Literature DB >> 23912251

Use of a low cut-off value for the fecal immunochemical test enables better detection of proximal neoplasia.

Jae Myung Cha1, Joung Il Lee, Kwang Ro Joo, Hyun Phil Shin, Jung Won Jeun, Jun Uk Lim.   

Abstract

BACKGROUND: The advantage of the quantitative fecal immunochemical test (FIT) is the flexibility to set the positivity threshold. However, the diagnostic success of the FIT has not been compared for standard and low cut-off thresholds. AIMS: The purpose of this study was to compare the diagnostic success of FIT for standard and low cut-off thresholds.
METHODS: In 2009 and 2010 a standard cut-off threshold (20 μg Hb/g feces) was used as positivity criterion for the FIT; in 2012 a low cut-off (10 μg Hb/g feces) was used. Diagnostic success was compared between the two groups.
RESULTS: Of the total of 14,289 participants, 195 (1.4 %) had positive FIT results. Positivity of the FIT was significantly higher in the low cut-off group than in the standard cut-off group (1.8 vs. 1.0 %, p = 0.000). Although detection of advanced neoplasia lesions was comparable, proximal neoplasia was more frequently detected in the low cut-off group (33.3 vs. 20.9 %, p = 0.016). With the low cut-off threshold, 39 (0.7 %) participants were also classified as having positive results, and 18 (46.2 %) of these had colorectal neoplasias. The number of positive results from the FIT was increased by 54.9 %, and detection of advanced neoplasia was increased by 60 % with the low cut-off threshold compared with the standard cut-off.
CONCLUSIONS: A low cut-off threshold for the FIT resulted in better detection of proximal neoplasia in population-based screening. These results indicate the cut-off threshold for positive FIT should be properly chosen and adjusted in colorectal cancer screening.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23912251     DOI: 10.1007/s10620-013-2819-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  36 in total

1.  Screening for colorectal cancer in Uruguay with an immunochemical faecal occult blood test.

Authors:  Eduardo Fenocchi; Luz Martínez; Julio Tolve; Daniel Montano; Mariella Rondán; Adolfo Parra-Blanco; Yoshinobu Eishi
Journal:  Eur J Cancer Prev       Date:  2006-10       Impact factor: 2.497

2.  A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds.

Authors:  O D Jørgensen; O Kronborg; C Fenger
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

3.  A quantitative immunochemical fecal occult blood test for colorectal neoplasia.

Authors:  Zohar Levi; Paul Rozen; Rachel Hazazi; Alex Vilkin; Amal Waked; Eran Maoz; Shlomo Birkenfeld; Moshe Leshno; Yaron Niv
Journal:  Ann Intern Med       Date:  2007-02-20       Impact factor: 25.391

4.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.

Authors:  J D Hardcastle; J O Chamberlain; M H Robinson; S M Moss; S S Amar; T W Balfour; P D James; C M Mangham
Journal:  Lancet       Date:  1996-11-30       Impact factor: 79.321

5.  Association of colonoscopy and death from colorectal cancer.

Authors:  Nancy N Baxter; Meredith A Goldwasser; Lawrence F Paszat; Refik Saskin; David R Urbach; Linda Rabeneck
Journal:  Ann Intern Med       Date:  2008-12-15       Impact factor: 25.391

6.  Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy.

Authors:  S J Winawer; B J Flehinger; D Schottenfeld; D G Miller
Journal:  J Natl Cancer Inst       Date:  1993-08-18       Impact factor: 13.506

7.  Cancer control activities in the Republic of Korea.

Authors:  Keun-Young Yoo
Journal:  Jpn J Clin Oncol       Date:  2008-04-11       Impact factor: 3.019

8.  Evaluation of diagnostic accuracy of screening by fecal occult blood testing (FOBT). Comparison of FOB Gold and OC Sensor assays in a consecutive prospective screening series.

Authors:  T Rubeca; S Rapi; M Confortini; M Brogioni; G Grazzini; M Zappa; D Puliti; G Castiglione; S Ciatto
Journal:  Int J Biol Markers       Date:  2006 Jul-Sep       Impact factor: 3.248

9.  Results of colorectal cancer screening of the national cancer screening program in Korea, 2008.

Authors:  Jung Im Shim; Yeonju Kim; Mi Ah Han; Hoo-Yeon Lee; Kui Sun Choi; Jae Kwan Jun; Eun-Cheol Park
Journal:  Cancer Res Treat       Date:  2010-12-31       Impact factor: 4.679

10.  Increasing uptake of colorectal cancer screening in Korea: a population-based study.

Authors:  Kui Son Choi; Jae Kwan Jun; Hoo-Yeon Lee; Myung-Il Hahm; Jae Hwan Oh; Eun-Cheol Park
Journal:  BMC Public Health       Date:  2010-05-21       Impact factor: 3.295

View more
  4 in total

1.  Does Low Threshold Value Use Improve Proximal Neoplasia Detection by Fecal Immunochemical Test?

Authors:  Nam Hee Kim; Hyo-Joon Yang; Soo-Kyung Park; Jung Ho Park; Dong Il Park; Chong Il Sohn; Kyuyong Choi; Yoon Suk Jung
Journal:  Dig Dis Sci       Date:  2016-04-23       Impact factor: 3.199

Review 2.  Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer.

Authors:  Douglas J Robertson; Jeffrey K Lee; C Richard Boland; Jason A Dominitz; Francis M Giardiello; David A Johnson; Tonya Kaltenbach; David Lieberman; Theodore R Levin; Douglas K Rex
Journal:  Am J Gastroenterol       Date:  2016-10-18       Impact factor: 10.864

3.  Colorectal cancer screening programme: is the French faecal immunological test (FIT) threshold optimal?

Authors:  Anna Pellat; Jacques Deyra; Marie Husson; Robert Benamouzig; Romain Coriat; Stanislas Chaussade
Journal:  Therap Adv Gastroenterol       Date:  2021-05-07       Impact factor: 4.409

4.  Performance of a quantitative fecal immunochemical test for detecting advanced colorectal neoplasia: a prospective cohort study.

Authors:  Elizabeth G Liles; Nancy Perrin; Ana G Rosales; David H Smith; Adrianne C Feldstein; David M Mosen; Theodore R Levin
Journal:  BMC Cancer       Date:  2018-05-02       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.